<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738539</url>
  </required_header>
  <id_info>
    <org_study_id>HSR200346</org_study_id>
    <nct_id>NCT04738539</nct_id>
  </id_info>
  <brief_title>Efficacy of Contrast Enhanced Voiding Urosonography for Urodynamic Studies</brief_title>
  <official_title>Efficacy of Contrast Enhanced Voiding Urosonography for Urodynamic Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will assess the feasibility of replacing fluoroscopy/iodinated contrast&#xD;
      with ultrasound/sulfur hexafluoride lipid-type A microspheres during routine urodynamic&#xD;
      studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urodynamic studies routinely involve instillation of iohexol (OmnipaqueTM), a low osmolality&#xD;
      contrast agent, into the bladder followed by fluoroscopic imaging to assess for reflux or&#xD;
      variant anatomy of the genitourinary system. Recently, sulfur hexafluoride lipid-type A&#xD;
      microspheres (LumasonTM), an ultrasound contrast agent, has been approved in the United&#xD;
      States for intravesicular administration in the pediatric population. Contrast enhanced&#xD;
      voiding urosonography (CEvUS) is being increasingly utilized in the place of voiding&#xD;
      cystourethrograms, with the major advantages being decreased (zero) radiation for the&#xD;
      patient, as well as decreased cost. Given the similarity in procedure between urodynamic&#xD;
      studies (UDS) and voiding cystourethrograms, we hypothesize that a urodynamic study may be&#xD;
      performed with contrast enhanced ultrasound instead of fluoroscopy. We plan to continue&#xD;
      enrollment from our feasibility study and perform an efficacy study by recruiting a group of&#xD;
      105 patients under the age of 18, who are willing to undergo their normally schedule UDS&#xD;
      using CEvUS to image the study in place of fluoroscopy. The UDS typically consists of two&#xD;
      cycles of bladder filling and voiding; we intend replace the use of fluoroscopy and iohexel&#xD;
      with ultrasound and sulfur hexafluoride lipid-type A microspheres. This will decrease the&#xD;
      time commitment and eliminate radiation exposure for the patient. Data to be analyzed will&#xD;
      include images from the study and patient/caregiver preference. Results from the ceVUS images&#xD;
      will be compared to images obtained during previous tests imaged with fluoroscopy from the&#xD;
      same patients currently enrolled in this study. Bladder shape and morphology, bladder neck&#xD;
      configuration and performance, structure of the urethra, presence and degree of&#xD;
      vesicoureteral reflux, and active voiding images will all be compared to fluoroscopy images&#xD;
      from previous studies. The purpose of the study is to demonstrate that ceVUS is effective as&#xD;
      an imaging technique for urodynamic studies, with an ultimate goal of using ceVUS instead of&#xD;
      fluoroscopy in all urodynamic and voiding studies in order to decrease pediatric radiation&#xD;
      exposure. The hypothesis is that ceVUS will be as effective for imaging urodynamics studies&#xD;
      as fluoroscopy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">March 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bladder shape and morphology</measure>
    <time_frame>Procedure (At time of urodynamic investigation)</time_frame>
    <description>Comparison of previous fluroscopy images and ceVUS images</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bladder neck configuration</measure>
    <time_frame>Procedure (At time of urodynamic investigation)</time_frame>
    <description>Comparison of previous fluroscopy images and ceVUS images</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Structure of urethra</measure>
    <time_frame>Procedure (At time of urodynamic investigation)</time_frame>
    <description>Comparison of previous fluroscopy images and ceVUS images</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence and degree of VUR</measure>
    <time_frame>Procedure (At time of urodynamic investigation)</time_frame>
    <description>Comparison of previous fluroscopy images and ceVUS images</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Images of active voiding</measure>
    <time_frame>Procedure (At time of urodynamic investigation)</time_frame>
    <description>Comparison of previous fluroscopy images and ceVUS images</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient/caregiver preference</measure>
    <time_frame>Immediately following urodynamic investigation or up to 7 days after by phone</time_frame>
    <description>Comparison survey</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Myelomeningocele</condition>
  <condition>Neurogenic Bladder</condition>
  <condition>Tethered Cord Syndrome</condition>
  <condition>Bladder, Neurogenic</condition>
  <condition>Urologic Diseases</condition>
  <condition>Neurologic Dysfunction</condition>
  <arm_group>
    <arm_group_label>Patients with or being evaluated for neurogenic bladder</arm_group_label>
    <description>Pediatric patients presenting to UVA Pediatric Urology for follow up or repeat urodynamics testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Contrast Enhanced Voiding Urosonography with Urodynamic Testing</intervention_name>
    <description>We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.</description>
    <arm_group_label>Patients with or being evaluated for neurogenic bladder</arm_group_label>
    <other_name>CeVUS</other_name>
    <other_name>Contrast Enhanced Voiding Urosonography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Urodynamic Testing</intervention_name>
    <description>We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.</description>
    <arm_group_label>Patients with or being evaluated for neurogenic bladder</arm_group_label>
    <other_name>Urodynamics</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric patients presenting to UVA Pediatric Urology for follow up or repeat urodynamics&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 0-17&#xD;
&#xD;
          -  Must have had prior urodynamic study at UVA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women (self-reported)&#xD;
&#xD;
          -  Fetuses&#xD;
&#xD;
          -  Neonates&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Subjects with preexisting cardiac conditions (such as CHF and ventricular arrhythmias)&#xD;
&#xD;
          -  Subjects with a known hypersensitivity to Lumason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nora G Kern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan V Leroy, MSN</last_name>
    <phone>434-924-0123</phone>
    <email>svg5m@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nora G Kern, MD</last_name>
    <phone>434-924-0123</phone>
    <email>ngl2z@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Leroy, MSN</last_name>
      <phone>434-924-0123</phone>
      <email>svg5m@virginia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrials.gov/ct2/show/NCT04170413?term=lumason&amp;cond=Neurogenic+Bladder&amp;cntry=US&amp;state=US%3AVA&amp;city=Charlottesville&amp;draw=2&amp;rank=1</url>
    <description>Feasibility of Using Contrast Enhanced Voiding Urosonography (CeVUS) During Urodynamic Studies (NCT04170413)</description>
  </link>
  <reference>
    <citation>Drzewiecki BA, Bauer SB. Urodynamic testing in children: indications, technique, interpretation and significance. J Urol. 2011 Oct;186(4):1190-7. doi: 10.1016/j.juro.2011.02.2692. Epub 2011 Aug 16. Review.</citation>
    <PMID>21849190</PMID>
  </reference>
  <reference>
    <citation>Fernbach SK, Feinstein KA, Schmidt MB. Pediatric voiding cystourethrography: a pictorial guide. Radiographics. 2000 Jan-Feb;20(1):155-68; discussion 168-71. Review.</citation>
    <PMID>10682779</PMID>
  </reference>
  <reference>
    <citation>Mane N, Sharma A, Patil A, Gadekar C, Andankar M, Pathak H. Comparison of contrast-enhanced voiding urosonography with voiding cystourethrography in pediatric vesicoureteral reflux. Turk J Urol. 2018 May;44(3):261-267. doi: 10.5152/tud.2018.76702. Epub 2018 Mar 6.</citation>
    <PMID>29733800</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Nora Kern, MD</investigator_full_name>
    <investigator_title>Associate Professor, Department of Urology</investigator_title>
  </responsible_party>
  <keyword>Contrast Enhanced Voiding Urosonography</keyword>
  <keyword>Urodynamics</keyword>
  <keyword>Neurogenic Bladder</keyword>
  <keyword>Detrusor Sphincter Dyssynergia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
    <mesh_term>Meningomyelocele</mesh_term>
    <mesh_term>Spina Bifida Cystica</mesh_term>
    <mesh_term>Neurologic Manifestations</mesh_term>
    <mesh_term>Neural Tube Defects</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

